Shaw C D, Carter K C
Strathclyde Institute of Pharmacy & Biomedical Sciences University of Strathclyde, 161 Cathedral Street, Glasgow, G4 0RE, Scotland, UK.
Nanomedicine (Lond). 2014 Jul;9(10):1531-44. doi: 10.2217/nnm.14.66.
Leishmaniasis is a disease caused by infection with the protozoan parasite Leishmania, which is responsible for three main types of disease: cutaneous leishmaniasis, visceral leishmaniasis and mucocutaneous leishmaniasis based to the site of infection for the particular species. This presents a major challenge to successful drug treatment, as a drug must not only reach antileishmanial concentrations in infected macrophages, the parasites' host cell, but also reach infected cells in locations specific to the type of disease. In this paper we discuss how studies using Leishmania have contributed to our knowledge on how drug delivery systems can be used to improve drug efficacy and delivery.
利什曼病是由原生动物寄生虫利什曼原虫感染引起的疾病,根据特定物种的感染部位,利什曼原虫可导致三种主要类型的疾病:皮肤利什曼病、内脏利什曼病和黏膜皮肤利什曼病。这给成功的药物治疗带来了重大挑战,因为一种药物不仅必须在被感染的巨噬细胞(寄生虫的宿主细胞)中达到抗利什曼原虫的浓度,而且还必须在特定于疾病类型的部位到达被感染的细胞。在本文中,我们讨论了使用利什曼原虫的研究如何增进了我们对药物递送系统如何用于提高药物疗效和递送的认识。